Acorda Therapeutics Inc  

(Public, NASDAQ:ACOR)   Watch this stock  
Find more results for ACOR
26.05
-0.35 (-1.33%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 24.40 - 26.80
52 week 13.60 - 33.00
Open 26.00
Vol / Avg. 1.51M/734,521.00
Mkt cap 1.20B
P/E     -
Div/yield     -
EPS -4.84
Shares 46.72M
Beta 1.63
Inst. own 109%
Apr 25, 2018
Q1 2018 Acorda Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 13, 2018
Acorda Therapeutics Inc at Cowen Health care Conference - 10:00AM EDT - Add to calendar
Feb 15, 2018
Acorda Therapeutics Inc at Leerink Partners Global Healthcare Conference
Feb 15, 2018
Q4 2017 Acorda Therapeutics Inc Earnings Release
Feb 15, 2018
Q4 2017 Acorda Therapeutics Inc Earnings Call - Webcast
Jan 10, 2018
Acorda Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
Nov 28, 2017
Acorda Therapeutics Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -90.80% -37.97%
Operating margin -115.75% -39.57%
EBITD margin - 10.92%
Return on average assets -53.96% -17.59%
Return on average equity -114.36% -37.72%
Employees 597 -
CDP Score - -

Address

420 Saw Mill River Rd
ARDSLEY, NY 10502-2605
United States - Map
+1-914-3474300 (Phone)
+1-914-3474560 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.

Officers and directors

Ron Cohen President,Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Batycky Ph.D. Chief Technology Officer and Site Head
Age: 49
Bio & Compensation  - Reuters
David Lawrence Chief Business Operations, Principal Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Andrew R. Blight Ph.D. Chief Scientific Officer
Age: 66
Bio & Compensation  - Reuters
Jane Wasman J.D. President - International, General Counsel, Corporate Secretary
Age: 61
Bio & Compensation  - Reuters
Burkhard Blank M.D. Chief Medical Officer
Age: 62
Bio & Compensation  - Reuters
Andrew Hindman Chief Business Development Officer
Age: 44
Bio & Compensation  - Reuters
Lauren M. Sabella Chief Commercial Officer
Age: 56
Bio & Compensation  - Reuters
Barry E. Greene Independent Director
Age: 53
Bio & Compensation  - Reuters
Peder K. Jensen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters